$3.65−0.23 (−5.93%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Anbio Biotechnology (NNNN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
11 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 63% below its peak, net margin 74.1%.
The lines that matter · FY22–FY25
Revenue ($K)▲5.6%
8,646.8
FY22→FY25CAGR −28.4%/yr
Net income ($K)▲169.9%
6,403.5
FY22→FY25CAGR −13.8%/yr
What the income statement says · FY22–FY25
Where every revenue dollar goes · FY25 ($K)
74¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 53.4% → 87.2%. Net margin 74.1% is more than double the sector median.
The receipt · income statement · FY22–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | FY25 † | FY25 | FY24 | FY23 | FY22 | YoY | CAGR 22→25 |
|---|---|---|---|---|---|---|---|
| Revenue & profitability | |||||||
Revenue | 8,646.8 | 8,646.8 | 8,185.1 | 6,712.0 | 23,544.7 | ▲5.6% | −28.4% |
Cost of revenue | 1,103.7 | 1,103.7 | 2,299.8 | 3,351.1 | 10,980.8 | ▼52.0% | −53.5% |
Gross profit | 7,543.2 | 7,543.2 | 5,885.4 | 3,360.9 | 12,563.8 | ▲28.2% | −15.6% |
Research & development | 201.3 | 201.3 | 454.2 | 134.7 | 200.0 | ▼55.7% | +0.2% |
Selling, general & admin | 1,574.1 | 1,574.1 | 3,435.8 | 1,265.2 | 2,168.2 | ▼54.2% | −10.1% |
Total operating expenses | 1,775.4 | 1,775.4 | 3,890.0 | 1,399.9 | 2,368.2 | ▼54.4% | −9.2% |
Operating incomefeeds ROC rank | 5,767.7 | 5,767.7 | 1,995.4 | 1,960.9 | 10,195.6 | ▲189.1% | −17.3% |
Other income, net | 635.7 | 635.7 | 377.5 | 292.8 | −184.4 | — | — |
Pretax income | 6,403.5 | 6,403.5 | 2,372.8 | 2,253.7 | 10,011.2 | ▲169.9% | −13.8% |
Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 6,403.5 | 6,403.5 | 2,372.8 | 2,253.7 | 10,011.2 | ▲169.9% | −13.8% |
| Per share | |||||||
Diluted EPSbuyback-sensitive | — | —A | —A | —A | —A | — | — |
Diluted shares (mn) | 143.89 | 143.89 | 142.29 | — | — | ▲1.1% | — |
| Margins | |||||||
Gross margin | 87.2% | 87.2% | 71.9% | 50.1% | 53.4% | ▲15.3pp | +33.9pp |
Operating margin | 66.7% | 66.7% | 24.4% | 29.2% | 43.3% | ▲42.3pp | +23.4pp |
Net margin | 74.1% | 74.1% | 29.0% | 33.6% | 42.5% | ▲45.1pp | +31.5pp |
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.A Withheld by our checks.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-04-07 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Anbio Biotechnology's revenue last fiscal year?
Anbio Biotechnology reported revenue of $8,646.8K in fiscal 2025, up 5.6% from fiscal 2024.
What was Anbio Biotechnology's net income?
Anbio Biotechnology reported net income of $6,403.5K in fiscal 2025, a net margin of 74.1%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

